We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Coherus BioSciences Inc | NASDAQ:CHRS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -2.20% | 1.78 | 1.59 | 1.80 | 1.83 | 1.74 | 1.83 | 712,115 | 05:00:01 |
From Dec 2023 to Jun 2024
By Ben Glickman
Coherus BioSciences has received approval from the U.S. Food and Drug Administration for an on-body injector of Udenyca, its cancer treatment.
The Redwood City, Calif.-based cancer-treatment developer's Udenyca Onbody was previously rejected by the FDA due to issues at a third-party filler. The company resubmitted its application weeks after.
Coherus said Tuesday that it expected Udenyca to be available commercially in the first quarter of 2024.
Udenyca is a cancer treatment administered the day after chemotherapy to reduce infections.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 26, 2023 16:28 ET (21:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Coherus BioSciences Chart |
1 Month Coherus BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
